Leadership
Epi One's leadership team is comprised of an unrivalled blend of individuals with industry-leading cancer-specific scientific expertise and international business experience.
Sophia F. Fang, MD & PhD
Co-CEO, President & CSO
With both MD and Ph.D. training, Sophia brings a proven record of translating cutting-edge research into clinical success.
Sophia is responsible for scientific strategy, research operations, and growing the company’s scientific team. Prior to co-founding Epi One, Sophia was a senior scientist at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. Her research was focused on human genomics and translational cancer biology. Sophia has an MD from Harbin Medical University and a Ph.D. in Bioinformatics and Computational Biology from Iowa State University and serves as Chair of Epi One's Board of Directors.
John Meduri
Co-CEO
John J Meduri is an in-vitro diagnostics (IVD) industry veteran with over 40 years leading global commercialization, strategic marketing, and business development in the diagnostics and life sciences industries. He has held leadership roles at Becton Dickinson, MRL Pharmaceutical Services and Accelerate Diagnostics with a proven track record of launching transformative IVD platforms, driving M&A activity, and building high-performing
global teams.
Mr. Meduri is a Wharton Fellow from The Wharton School at the University of Pennsylvania and is also the recipient of The Distinguished Alumnus Award from The Johns Hopkins University Alumni Association.
Neng Yang, MD & PhD
Co-Founder, Vice President R&D
Neng is an expert in next-generation sequencing technology, immunology, and CAR T-cell immunotherapy.
Neng conducts day-to-day experiments for the cancer detection biomarkers’ clinical validation. Prior to co-founding Epi One she was a research associate at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. She established a novel single cell sorting and sequencing technology to understand the genetic heterogeneity of leukemia. She also conducted research on CAR T-cell therapy for lung cancer patients. Neng has an MD from Guangdong Medical College and a Ph.D. from ShangHai JiaoTong University and serves on Epi One's Board of Directors.
MinKui Luo, PhD
Dr. Luo is a full professor at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interest in discovery research at the interface of chemistry and biology. Specifically, Dr. Luo focuses on studying epigenetic writers (PMTs), readers (Rme/Kme effectors) and erasers (demethylases) with functional relevance to noncanonical histone methylation, protein homeostasis and transcription plasticity
Greg Papaz
Greg is a proven leader in the Biotech and pharmaceutical industry. He has operational success in large multi-national, mid-cap and early-stage, start-up companies. He has expertise in driving commercial business, building start-up organizations, crafting strategic plans for developmental compounds, launching products, raising capital and forging strategic alliances. Piror Newfield Therapeutics Greg was the president and CEO of PAION Inc. (a subsidiary of PAION AG, Germany).